欢迎访问《现代生物医学进展》编辑部！

目的：探讨3例眼眶恶性肿瘤碳离子放射治疗（CIRT）的疗效及安全性。方法：回顾性分析2022年7月至2023 年7月于甘肃省武威肿瘤医院接受CIRT治疗的3例眼眶恶性肿瘤患者的临床资料，并复习相关文献。结果：3例患者均完成CIRT治疗，平均随访20.50个月（15-26个月）。病例1经CIRT治疗后3个月达到完全缓解（CR），病例2经CIRT治疗后3个月达到CR，病例3经CIRT治疗后12月达到部分缓解（PR）。3例患者的1年局部控制率（LC）、1年无进展生存率（PFS）、1年总生存率（OS）均为 100.00%。1例患者发生1级放射性结膜损伤，2例患者发生1级放射性皮肤损伤，1例患者发生1级眼干的放疗晚期不良反应；所有患者均未发生2级及以上的不良反应。结论: CIRT应用于不可手术切除、术后残留及复发的眼眶恶性肿瘤可获得良好的OS和 LC，且急性和晚期毒性反应较少。

英文摘要:

Objective: To investigate the efficacy and safety of carbon ion radiotherapy (CIRT) in 3 cases of orbital malignant tumors. Methods: The clinical data of 3 patients with orbital malignant tumor who received CIRT treatment in Wuwei Cancer Hospital of Gansu Province from July 2022 to July 2023 were retrospectively analyzed, and the relevant literature was reviewed. Results: Three patients completed CIRT treatment, they were followed up for an average of 20.5 months (15-26 months). Case 1 achieved complete response (CR) 3 months after CIRT treatment, case 2 achieved CR 3 months after CIRT treatment, and case 3 achieved partial response (PR) 12 months after CIRT treatment. The 1 year local control rate (LC), 1-year progression-free survival (PFS), and 1-year overall survival (OS) of the three patients were 100.00%. One patient had grade 1 radiation conjunctival injury, 2 patients had grade 1 radiation skin injury, and 1 patient had grade 1 dry eye late adverse reaction. No adverse reactions of grade 2 or higher occurred in all patients. Conclusion: The application of CIRT in unresectable, postoperative residual and recurrent orbital malignant tumors can obtain good OS and LC, and acute and late toxic reactions are less.

View Fulltext 查看/发表评论下载PDF阅读器

关闭